focus -WSS

focus

author：knowledge 2025-09-05 05:55:19 - browse：83

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Quicker fix for pulse oximeters urged during FDA public meeting

hotspot

WSS

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Why sickle cell disease is getting the first CRISPR treatment

Radiology is caught between AI's potential and concern for patients

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

The woman behind the Dana Farber

What causes an itch? Researchers may have solved the mystery

Wikipedia

focus

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Cognito secures funding to test medical device for Alzheimer's

Medicare proposal to cover medical devices draws a mixed reaction

Americans' trust in science, scientist continues decline: Report

Peter Hotez and the public health issue of online harassment

SAMSHA loosens regulations on methadone treatment centers

Medical leaders decry Supreme Court decision on affirmative action

Patients' immediate access to test results puts radiologists in a bind

Tori Bowie and the unacceptable rates of Black maternal death

Covid misinformation case heads to Supreme Court

leisure time

Roche to buy Carmot Therapeutics, developer of obesity drugs

Juul spent big to court Black leaders to promote its e

Medicare drug price negotiation’s day in court

Vertigo drug brings hope for rare neuron disorder, Niemann

Cybersecurity threat forces Lurie Children's to take systems offline

Chemotherapy shortages won’t get better under Biden’s latest plan

hotspot

entertainment

focus

focus